The quality of life of patients with periodontal diseases and investigation of the lipid-A based biomarkers as potential diagnostic tool

The University of Sydney0 个研究点目标入组 90 人开始时间: 2022年2月7日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1.Periodontally healthy patients (participants)
•2.Periodontally diseased patients with plaque-induced gingivitis and patients with periodontitis stage II, III or IV
•3.Gender: no restrictions
•4.Age range: >18 years
•5.Patients (participants) in good systemic health (ASA class 1 and 2)
•6.Patients (participants) from all dietary backgrounds
•7.Willingness to provide informed consent and willingness to participate and comply with the study requirements and protocol.
•8.Patients who have not been treated from periodontal diseases in the previous 6 months and who are not currently receiving/undergoing periodontal therapy
•9.Patients that are not currently involved in periodontal maintenance program
•10.Women of childbearing potential who are using a reliable contraceptive method(s).

•1.Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
•2.Participants currently experiencing psychological illness or other conditions which may interfere with their ability to understand the study requirements or interfere with their motivation to participate in the study.
•3.Participants with a history of active periodontal treatment (subgingival instrumentation) in the previous 6 months.
•4.Participants who have taken antibiotics within the past 3 months.
•5.Patients taking non-steroidal anti-inflammatory medications or those who were on these medications in the past 4 weeks
•6.Patients who received any acute treatment or had acute diseases in previous 4 weeks
•7.Participants with a history of any serious and uncontrolled systemic diseases (ASA class 3-6)
•8.Participants on supportive periodontal therapy
•9.Participants unable to obtain sufficient level of oral hygiene for successful treatment outcomes (approximal plaque index API (35%) (Lange, 1975) and Sulcus bleeding index SBI (25%) Muhlemann, 1971)

发起方